Aspire Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aspire Biopharma Holdings, Inc. (ASBP) on January 30, 2026, reporting events occurring on January 26, 2026. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Estero, Florida.
Key Financial Metrics and Transaction Details
The filing details a specific financing transaction rather than periodic financial results. Key metrics from the transaction include:
- Debt Issued: Debentures with an aggregate principal amount of $2,173,913.04.
- Proceeds Received: $2,000,000 subscription price.
- Interest Rate: 8% Original Issue Discount (OID); no annual interest payments.
- Maturity Date: April 23, 2026.
- Equity Issued: 790,000 shares of common stock issued as incentive shares to purchasers.
- Use of Proceeds: Payoff of existing debt and working capital.
The filing text does not provide clear values for total revenue, net profit, operating cash flow, gross margins, total debt balance, or liquidity ratios as of the reporting date.
Material Changes and Terms
The material change is the entry into a Material Definitive Agreement for the issuance of short-term debt. Key terms include:
- Acceleration Clause: The Debentures are due at the sooner of 90 days from issuance or upon the Company's receipt of gross proceeds of at least $8,000,000 in any equity or debt financing.
- Prepayment: The Company has the option to prepay the Debentures at any time after the Original Issue Date at the Principal Amount.
- Notice Period: The Company must provide 10 Business Days' prior written notice for satisfaction of the Debentures.
- Convertibility: The Debentures are not convertible into common stock.
Outlook, Risks, and Contingencies
Management intends to utilize the proceeds to pay off debt and for working capital purposes. The transaction was offered in reliance on Section 4(a)(2) of the Securities Act of 1933 and was not registered. The filing does not provide specific forward-looking guidance, risk factors, or contingencies beyond the standard legal disclaimers regarding the unregistered nature of the securities.
Investor Verification Checklist
- Verify the Company's ability to repay the $2,173,913.04 principal by the April 23, 2026 maturity date or within 90 days.
- Assess the risk of immediate acceleration if the Company raises $8,000,000 or more in new financing before the maturity date.
- Confirm the impact of the 790,000 incentive shares on existing shareholder dilution.
- Review the specific debt obligations being paid off with the $2,000,000 proceeds to understand the net change in leverage.